DNMT1 and acute myeloid leukemia: Following the discovery of the dose-dependent mechanism of action of decitabine (a drug which serves as a cytostatic inhibitory nucleoside analog at high doses, and as a DNMT inhibitor with the potential to alter DNA methylation patterns at low doses), low-dose decitabine has become an important tool in the treatment of AML.